BIOA - Total Utang marang Modal BioAge Labs, Inc

Logo perusahaan publik BioAge Labs, Inc. (BIOA)

BioAge Labs, Inc. (BIOA) is establishing a robust component supply chain to prevent disruptions during drug testing. This price action on GURU.Markets reflects a total debt-to-equity ratio of 0.01. The company leverages artificial intelligence to discover treatments for aging and metabolism. However, the high concentration of development within a single narrow field creates significant risks typical of startups.

BIOA: Total Utang marang Modal BioAge 27.09.2024 - 30.10.2026

Rincian analitis perusahaan BioAge Labs, Inc.

- rega lan prakiraan konsensus rega:
Bagan rega BioAge|BIOA - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar BioAge Labs, Inc.|BIOA - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham BioAge Labs, Inc.|BIOA - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku bioagelabs.com|BIOA - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas BioAge Labs, Inc.|BIOA - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal BioAge Labs, Inc.|BIOA - Gunggung utang perusahaan|Utang marang nilai buku BioAge Labs, Inc.|BIOA - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan BioAge Labs, Inc.|Rasio cepet bioagelabs.com
- informasi bathi lan kelipatan valuasi:
BIOA - Penghasilan resik perusahaan
Analisis dhasar perusahaan:BioAge
Barang utama BioAge Labs, Inc

When constructing a long-term portfolio, it is critical to evaluate an issuer's financial stability through debt load analysis. This indicator compares total liabilities to equity, determining the business's degree of dependence on borrowed funds. For BioAge Labs, Inc. (BIOA), which invests in AI-driven development of anti-aging drugs, the leverage balance determines the scaling speed of its pipeline. The trend in the total debt-to-equity ratio visualizes the company's current margin of safety.

Analisis pesaing BioAge Labs, Inc.

Utang marang Ekuitas Ascendis Pharma|Madrigal Pharmaceuticals Inc - Utang Agregat marang Ekuitas|Total Utang marang Modal CORT|RYTM (Rhythm Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal AKRO (Akero Therapeutics)|Total Utang marang Modal metsera.com MTSR|MLTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CRNX (Crinetics Pharmaceuticals, Inc.)|NewAmsterdam Pharma N.V. (NAMS) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Soleno Therapeutics Corp|FOLD (Amicus Therapeutics) - Total Utang marang Modal|Total Utang marang Modal 89bio.com|Rasio Total Utang marang Ekuitas AGIO (Agios Pharmaceuticals, Inc.)|GPCR (Structure Therapeutics Inc) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas MiMedx Group MDXG|RZLT - Rasio Total Utang marang Ekuitas|Lexicon Pharmaceuticals - Total Utang marang Modal|Utang marang Modal mbxbio.com|ALT (Altimmune) - Rasio Total Utang marang Ekuitas|AARD: Utang Agregat marang Modal|SGMT (Sagimet) - Total Utang marang Modal|Total Utang marang Modal Biomea Fusion Corp|Total Utang marang Modal QNCX|Utang marang Ekuitas GUTS (fractyl.com)|Utang marang Ekuitas vTv Therapeutics VTVT|Agape ATP Corp (ATPC) - Utang marang Modal|PLUR - Utang marang Ekuitas|SYBX: Utang marang Ekuitas|LPCN: Total Utang marang Modal|MTNB - Koefisien Total Utang marang Modal|Utang marang Ekuitas Spruce Biosciences, Inc.|Galecto Inc (GLTO) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Carmell Corp (CTCX)|Rasio Total Utang marang Ekuitas Lumos Therapeutics LUMO|Total Utang marang Modal ONVO (Organovo Holdings, Inc.)|radiuspharm.com - Utang marang Ekuitas